LifeStance to Present at the 46th Annual Goldman Sachs Healthcare Conference
Details of the presentation are as follows:Presenters: Dave Bourdon, CEO, and Ryan McGroarty, CFODate: Tuesday, June 10, 2025 Time: 10:40 a.m. (Eastern time)Moderated by: Jamie Perse
The presentation will be webcast live and will be available on the Events and Presentations section of the LifeStance Health Investor Relations website (https://investor.lifestance.com).
A replay of the webcast will be available after the conclusion of the event and can be accessed on the LifeStance Health Investor Relations website.
About LifeStance HealthFounded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental health care. LifeStance and its supported practices employ approximately 7,500 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.
CONTACT: Investor Contact: Monica Prokocki VP of Finance and Investor Relations investor.relations@lifestance.com Media Contact: Brooke Matthews Sr. Director of Communications media@lifestance.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Rumble Announces Timing of Second Quarter 2025 Earnings Release and Conference Call
By GlobeNewswire Published on August 2, 2025, 01:05 IST LONGBOAT KEY, FL, Aug. 01, 2025 (GLOBE NEWSWIRE) — Rumble Inc. (NASDAQ: RUM) ('Rumble' or the 'Company'), the video-sharing platform and cloud services provider, today announced that it will release financial results for the fiscal quarter ended June 30, 2025 before market open on Monday, August 11, 2025. The Company will host a conference call on the same day at 11:30 a.m. Eastern Time. Access to the live webcast and replay of the conference call, along with related earnings release materials, will be available here and on Rumble's Investor Relations website at ABOUT RUMBLE Rumble is a high-growth video platform and cloud services provider that is creating an independent infrastructure. Rumble's mission is to restore the internet to its roots by making it free and open once again. For more information, visit: For investor inquiries, please contact: Shannon Devine MZ Group, MZ North America 203-741-8811 [email protected] Source: Rumble Inc. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Medscape
4 hours ago
- Medscape
These Two Simple Interventions May Cut CRC Recurrence Risk
This transcript has been edited for clarity. Hello. I'm Dr David Johnson, professor of medicine and chief of gastroenterology at Eastern Virginia Medical School and Old Dominion University in Norfolk, Virginia. New guidelines have lowered the age to begin screening for colon cancer to 45 years old. Although this change is positive, we're still seeing advanced cancer in younger patients who haven't been screened in time. Once diagnosed, these patients undergo surgery and chemotherapy and often return to us asking, 'What can I do now to help myself?' Two recent studies highlight interventions that are simple, affordable, and actionable today: exercise and aspirin. Let's take a closer look at the results. Exercise's Risk Reduction Potential The idea that exercise reduces cancer recurrence and mortality is supported by observational data. The mechanistic effects behind this have been ascribed to metabolic growth factors, inflammatory changes, immune function changes, and perhaps even positive impact on sleep. A study just published in The New England Journal of Medicine examined structured exercise after adjuvant chemotherapy for colon cancer. The phase 3 randomized CHALLENGE trial, mostly conducted at Canadian and Australian centers, recruited patients with resected stage II or III colon cancer (9.8% and 90.2%, respectively) who had completed adjuvant chemotherapy. Patients with recurrences within a year of diagnosis were excluded, as they were more likely to have highly aggressive, biologically active disease. Patients were randomized to receive healthcare education materials alone or in conjunction with a structured exercise program over a 3-year follow-up period. The exercise intervention, delivered in person or virtually, focused on increasing recreational aerobic activity over baseline by at least 10 metabolic equivalent task (MET). An increment of 10 MET hours per week is not too vigorous. It is essentially the equivalent of adding about 45-60 minutes of brisk walking or 25-30 minutes of jogging 3-4 times a week. Patients were asked to increase MET over the first 6 months and then maintain or further increase the amount over the next 2.5 years. They were permitted to structure their own exercise program by choosing the type, frequency, intensity, and duration of aerobic exercise. The primary endpoint was disease-free survival, with secondary endpoints assessing overall survival, patient-reported outcomes, and other outcomes. Although designed to detect differences at 3 years, follow-up was also performed out to 5 and 8 years. At a median follow-up of 7.9 years, exercise reduced the relative risk of disease recurrence, new primary cancer, or death by 28% ( P =.02). This benefit persisted — and even strengthened — over time, with disease-free survival increasing by 6.4 and 7.1 percentage points at 5 and 8 years, respectively. Musculoskeletal adverse events were slightly higher in the exercise group compared with the health education group (18.5% vs 11.5%, respectively), but only 10% were directly attributed to the exercise. There are considerations when interpreting these results. First, there was an attrition over time for compliance and training. It would be interesting to see whether that impacted the results. Second, it's unclear whether patient pedigree or a genomic pathway may predispose to a benefit here for the exercise group. But overall, this phase 3 trial provides class 1 evidence supporting exercise as a low-cost, high-impact intervention to reduce cancer recurrence. Adjuvant Aspirin in Colon Cancer Subset That's a perfect segue into another recent study looking at the effects of adjuvant aspirin on the prevention of recurrence. The ALASCCA trial— conducted across centers in Sweden, Denmark, Finland, and Norway — assessed patients with stage I-III rectal cancer or stage II-III colon cancer. It focused on a subset of patients with an oncogenic abnormality called PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha). PIK3CA occurs in approximately a third of colon cancers and is associated with significant chemotherapy resistance and a higher rate of disease progression. Of the included patients, 1103 (37%) had alterations in the PIK3CA pathway. Researchers randomized patients to receive either 160 mg of aspirin or placebo daily for 3 years, starting within 3 months of surgery. Among patients with PIK3CA mutations, aspirin dramatically reduced the risk for time to recurrence by nearly 50% at 3 years ( P =.044). Adverse events associated with aspirin were minimal, including one case each of gastrointestinal bleeding, hematoma, and allergic reaction. There is no evidence that higher aspirin doses provide greater prevention of colorectal cancer recurrence. The 160 mg use in the current study is fairly normal, roughly equivalent to two low-dose (81 mg) aspirin tablets. Now, it's worth noting that the use of aspirin for the primary prevention of cardiovascular disease was initially recommended by the US Preventive Task Services Force in 2016. This recommendation was then recanted in 2022, when the same group reported limited net benefit to this approach. Two Proactive Actions These studies highlight two interventions — exercise and aspirin — that are low cost, accessible, and appeal to patients eager to help prevent their cancer from recurring. Exercise is broadly beneficial and can be recommended immediately. For aspirin, patients should work with their oncologist to determine their PIK3CA mutation status, as this subgroup appears to benefit the most. These findings offer patients meaningful, proactive interventions they can apply to support their recovery and reduce the risk of recurrence. Hopefully these new findings will help guide your clinical conversations. I'm Dr David Johnson. Thanks for listening.
Business Wire
6 hours ago
- Business Wire
Asana to Announce Second Quarter Fiscal Year 2026 Financial Results on Wednesday, September 3, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Asana, Inc. (NYSE: ASAN)(LTSE: ASAN), a leading work management platform for human + AI coordination, announced today that it will release financial results for the second quarter fiscal year 2026 on Wednesday, September 3, after the close of the U.S. markets. In conjunction with the announcement, the company will host a webcast on the same day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the financial results. The live webcast and replay will be available on the Asana Investor Relations website at About Asana Asana is a leading work management platform for human + AI coordination. Over 170,000 customers like Accenture, Amazon, Anthropic, Morningstar, and Suzuki rely on Asana to align teams and accelerate organizational impact. Whether it's managing strategic initiatives, cross-functional programs, or company-wide goals, Asana helps organizations bring clarity to complexity—turning plans into action with AI working alongside teams every step of the way. To learn more, visit
